chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Underlying hardened skin induration at site of injection  of size 5x3cm by day 3 Improving and decreased in size to 2x1cm by day 7 Pt seen at clinic on both  the above days
2 days of fatigue, 1 day diarrhea, 1 day mild fever and five days of a dry cough - all starting 3rd day after second vaccination
Tired, headache, felt hot, burning eyes (indicating fever).  102.3 fever when I arrived home at 8:00pm.  Took acetaminophen 600mg.  Felt fine the next day.
a week after the (2nd) vaccine, I developed a skin rash/hyper pigmentation all over right thigh, both left and right legs, behind the knees, and lower abdomen.  another week after this I started feeling tingling nerve sensations, like electrical spikes, in locations *not* corresponding with the skin rash, random "pins and needles" in fingertips, toes, shins, other areas.  the skin rash is still there, a bit less severe, 4+ months later,  but the "nerve spikes", which I am told is nerve damage, has gotten a bit more intense in the last few weeks.    It took me a while to realize that these were likely side effects of the vaccine and not some strong allergic reaction to something, I have since seen my PCP, two dermatologists/allergists, a neurologist, two rheumatologists,  and literally all of them concur that this is the vaccine, that they have seen similar cases (though rarely)  ALSO ? I have had insomnia, and learned that my Hashimoto's (autoimmune, thyroid) was suddenly acting up again, after being stable for 6+ years..
This spontaneous report as received from a nurse's aide refers to an unspecified number of patients of unknown age and gender. No information on patients medical history or concurrent conditions was provided. On an unknown dates, the patient were vaccinated with improperly stored doses of GARDASIL injection (strength, dose, route of administration, lot# and expiration date were not reported). No information on patients concomitant medications was provided. No adverse effects were reported. This is one of several reports from the same reporter. Additional information has been requested.
Pneumonia due to COVID-19 virus [U07.1, J12.82] COVID-19 [U07.1]   ADMISSION AND DISCHARGE DIAGNOSES:  HOSPITAL COURSE:   COVID PNA Possible superimposed bacterial PNA. Elevated procalcitonin  - s/p 3 doses of IV Remdesivir course. On room air. Asymptomatic  - Treated with IV Rocephin and azithromycin. Home on Ceftin, doxy x 2 additional days  - Negative strep and Legionella antigens   Deconditioning  -PT/OT with recs for home with home health and PT    Chronic diastolic heart failure  HTN HLD  Depression  - Continue home meds    Mild cognitive impairment -A&O 2-3 at baseline -continue home meds    CKD III
exposed to covid positive and tested positive after he got the first dose of the vaccine; exposed to covid positive and tested positive after he got the first dose of the vaccine; This is a spontaneous report from a Pfizer-sponsored program COVAX Support. A contactable consumer (patient's wife) reported for a male patient (reporter's husband) received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/lot number, Expiration date: unknown) via an unspecified route of administration in Feb2021 at single dose for COVID-19 Immunization. Patient medical history and concomitant medications were unknown. The caller reported that she and her husband got the first dose of the vaccine 2 weeks ago, and the patient (husband) exposed to covid positive and tested positive after patient got the first dose of the vaccine, also exposed to COVID positive but not tested positive however she is experiencing headache, cough, and sinus drainage, asked was it ok to get the second dose of the vaccine on the 03Mar2021. The patient underwent lab test included positive SARS-CoV-2 test. The outcome for the events were unknown at the time of report. Upon follow-up (24Feb2021): This is a follow-up spontaneous report from a Pfizer-sponsored program COVAX Support. A contactable consumer (patient's wife) reported for a male patient (reporter's husband) included no new information.  Information about lot/batch has been requested.
24 hrs - migraine, low grade fever, aches, flu symptoms. 48 hrs - swelling in all joints - joint pain, overall general bloating X 4 days. Fifth day - general improvement, still pain in (L) hip with walking, improving.
Left cheek on my face went numb; Swelling in my face; This is a spontaneous report from a contactable consumer. This consumer reported that for an unspecified age and gender patient received first dose of BNT162B2 (BNT162B2, Formulation was Solution for injection, Lot Number was AN6204, and expiration date was unknown), via unspecified route on 09Mar2021 as single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. Consumer stated, took the Pfizer vaccine and had the adverse reaction. I had the shot on the left side. On an unspecified date in 2021, My left cheek on my face went numb and I had some swelling in my face. It lasted about 48 hours and I was concerned about taking the second vaccine and how much the first vaccine actually protected to the patient. Consumer stated, second vaccine shot due on 30Mar2021. The outcome of both events was recovered in 2021.   No follow-up attempts are possible. No further information is expected.
w/in 1 hr pt became very irritable, crying; unconsolable; refused to nurse; leg hurt, mom gave pt tepid bath, still screamed for 3 hrs @ which time fell asleep (given APAP); face color dusky, greenish cast, t103 ax, inject site red & swolle
Inappropriate schedule of vaccine administered; Feeling unwell; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (Feeling unwell) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    No Medical History information was reported.   On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Solution for injection in pre-filled pen. In April 2021, the patient experienced MALAISE (Feeling unwell). On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered). At the time of the report, MALAISE (Feeling unwell) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) outcome was unknown.            No concomitant medication information was provided. In April 2021, the patient experienced felt under the weather after the second covid vaccination. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. No treatment medication was provided. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
tested positive for covid after both doses; tested positive for covid after both doses; This is a spontaneous report from a contactable consumer. This consumer reported for himself. This is 1 of the 3 report.  This is a spontaneous report from a contactable consumer. The report is from a facility regarding 3 residents at the facility who tested positive for COVID after receiving both doses of the vaccine. This is 1 of three reports. A 86-years-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, lot number: E10140 and Expiry date: 31Mar2021), via ) via intramuscular route on 13Jan2021 as a SINGLE DOSE for COVID-19 immunization. Medical history includes diabetes, heart disease, hypertension and Alzheimer's disease from unspecified-to-unspecified date. The historical vaccine patient received first dose of BNT162B2 (COMIRNATY, Formulation: Solution for injection, lot number: E10140 and Expiry date: 31Mar2021) 0.3ml via intramuscular route in the right upper arm on 23Dec2020 as a COVID-19 immunization. There were no concomitant medications reported. On 30Mar2021 the patient tested positive for COVID after both doses. The patient underwent lab tests and procedures which included COVID-19 PCR test which was positive on 30Mar2021. Outcome of the events was unknown.
PAIN IN CHEST; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age, sex, race and ethnicity. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. On an unspecified date, the patient was previously received covid-19 vaccine ad26. cov2. s from an unspecified manufacturer (dose number in series: 1) (suspension for injection, route of admin, and batch number: unknown, expiry: unknown), dose was not reported, 1 in total administered for prophylactic vaccination. It was unknown whether patient had any adverse event following covid-19 vaccine (Dose number in series 1). The patient received covid-19 vaccine ad26.cov2.s (dose number in series: 2) (suspension for injection, route of admin, and batch number: unknown, expiry: unknown) dose, start therapy date were not reported, 1 total, administered  for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On an unspecified date, following vaccination with covid-19 vaccine ad26.cov2.s, the patient experienced pain in chest which goes away and comes again while working (Dose number in series 2). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from pain in chest. This report was non-serious.
Patient got 2nd dose of pfizer instead of Moderna 2nd dose; This spontaneous case was reported by a pharmacist and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (Patient got 2nd dose of pfizer instead of Moderna 2nd dose) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029A21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Patient got 2nd dose of pfizer instead of Moderna 2nd dose). At the time of the report, INTERCHANGE OF VACCINE PRODUCTS (Patient got 2nd dose of pfizer instead of Moderna 2nd dose) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient received the first dose of the Moderna COVID-19 approximately 28 days prior to receiving the Pfizer COVID-19 vaccine (date of vaccination for Pfizer not provided).   No concomitant medications were reported.  No treatment information was provided.
Client reported that about one hour after receiving the Janssen COVID vaccine, she developed tingling along the back of her left thigh below her buttocks and lasted about 2-3 hours. The client denied experiencing the tingling anywhere else. The client denied any other symptoms. The client has no known allergies.
Ringing in ear. Loud buzz . Was non stop for awhile. Now it gets a bit lower at times. It is mainly in the left ear.
I developed this constant pitch in my ears that won?t go away almost like a messed up radio or antenna signal.
About a 1/2 hour after getting her flu shot, pt. noticed her arm was itching. Once she got home she noticed the injection site was red and puffy, after a couple days redness went away and area turned green.
pt recvd 1st dose of Engerix-B 21AUg92 & exp migraine h/a that lasted for 12 hrs; pt was prev hx of migraine h/a;
Information has been received from a health professional concerning a 16 year old male with a history of seizures who on 07-Sep-2005 was vaccinated with a 0.5 mL dose of varicella virus vaccine live.  There was no concomitant medication.  On 10-Sep-2005, the patient returned to the physician's office and was diagnosed with chickenpox.  Unspecified medical attention was sought.  No laboratory or diagnostic tests were performed.  At the time of this report, the patient had not recovered.  No product quality complaint was involved.    Additional information has been requested.
Pt vaccinated with DTP/OPV developed extreme irritability & was tired & layed around. Also PE: didn't show sign, hypotonia, neurological exam & VS OK.
This spontaneous report was received from a 65 year old male patient, regarding himself. The patient's medical history included shingles about 40 years ago. There were no concurrent conditions, drug reactions/allergies and concomitant medications reported. Approximately in 2016, the patient was vaccinated with ZOSTAVAX (dosing details not provided) for prevention of shingles. On 18-OCT-2018, the patient experienced shingles. He sought medical attention and visited his physician on an unknown date. He was treated with unspecified antiviral medication and gabapentin for about 1 week. Outcome of the event was reported as recovering. Causality assessment was not provided.
patient was administrated with an expired dose / expired on May 25 2021; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 16-month-old male patient who received DTPa (Infanrix) (batch number G5BE3, expiry date 25th May 2021) for prophylaxis.   Co-suspect products included dtpa vaccine pre-filled syringe device (Infanrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 14th June 2021, the patient received Infanrix and Infanrix Pre-Filled Syringe Device. On 14th June 2021, unknown after receiving Infanrix and Infanrix Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The age at the vaccination was not reported. The patient was administered Infanrix, which was already expired on 25th May 2021. No adverse event was reported. The reporter consented to follow up.
I had a flu shot in the morning at around 10am  in center and I started to experience sever symptom of flue in the afternoon and the flue symptom continues last night and now. I don't know how many days it will last. That is why I want to report. I am sure that my flue was triggered by flu shot because I don't have this type of flue symptoms for long time, but immediate after the flu shot.
I was sick with a sore throat and runny nose on 12/12/2022. I went to my PCP where they did Strep test which negative. And I also did a COVID-19 home test on 12/12/2022 and 12/13/2022 both days were negative. On 12/21/2022 I had a cough in the afternoon around 03:00PM. I had very mild symptoms so I didn't get care from my doctor. I took over the counter congestions & headaches medication from the pharmacy for 2 days. I still have a mild cough as of 12/27/2022. I am recovering.
This case was reported by a pharmacist via call center representative and described the occurrence of suspected vaccination failure in a female patient who received SHINGRIX for prophylaxis. In December 2018, the patient received SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles and rash. On an unknown date, the outcome of the vaccination failure, shingles and rash were unknown.  It was unknown if the reporter considered the vaccination failure, shingles and rash to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient received SHINGRIX and experienced active rash of shingles. This case was considered as suspected vaccination failure since the details regarding completion of primary vaccination schedule, time to onset and laboratory confirmation were unknown at the time of reporting. Limited information was provided.
Prior to vaccination patient reported dizziness and headache to nurse that started approximately 20 minutes before her appointment.  Appointment was at 11:30. Heart Rate and oxygen in normal range. Blood pressure 144/90. Patient could not stand, headache and dizziness not subsiding. Patient taken by ambulance to nearest Emergency Department at approximately 1:25pm
This spontaneous report as received from a nurse refers to a 24 years old female patient with DEMEROL allergy and no other pertinent medical history. The patient was vaccinated with first dose of GARDASIL (lot #6700491/1171AA, expired date: 11-NOV-2013) on 21-FEB-2012. The patient was vaccinated with second dose of GARDASIL (lot # 672653/1860AA, expired date: 30-SEP-2014) on 24-APR-2012. The patient was vaccinated with third dose of GARDASIL (lot number reported as H010915, expired date: 13-FEB-2015) on 27-AUG-2012. No other co-suspects were reported. No concomitant medications were reported. After the third dose, in 2012, the patient experienced seizures and was hospitalized. The name of hospital was unspecified, exact date of hospitalization was unspecified. The outcome of seizures was reported as not recovered. Additional information has been requested.
Information has been received from a pharmacist referring to a patient of unknown age. On an unknown date in approximately 2013 ("about a year ago") the patient was vaccinated with first dose of ZOSTAVAX (lot #, dose and route were not reported). On approximately 25-NOV-2014 ("about two weeks ago") the patient was vaccinated with the second dose of ZOSTAVAX (lot #, dose and route were not reported), which was considered as an extra dose. No adverse events reported. Follow up information has been received from the pharmacist referring to the 73 year old female patient. On 25-FEB-2013, the patient was vaccinated with her second dose of ZOSTAVAX (lot # H020845, expiration date 20-FEB-2014) subcutaneously in the left arm, which was considered as an extra dose. No reaction was noted. Additional information is not expected since follow up information has been received. Reporter, patient, therapy, event and narrative were updated.
1/8/2023  I had congestion and a terrible headache and had a terrible night?s sleep. I tested positive for COVID with an at home COVID test on 1/9/23. I called my physician and he prescribed Paxlovid which I began taking.  I tested negative for COVID on 1/26/23.   I had mostly congestion.   Most symptoms had abated.
The vial expired on 01-Apr-2022 that was initially stored in the refrigerator on 04-Apr-2022 and then administered on 04-Apr-2022; Expired vaccine administered to patient; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine administered to patient) and PRODUCT STORAGE ERROR (The vial expired on 01-Apr-2022 that was initially stored in the refrigerator on 04-Apr-2022 and then administered on 04-Apr-2022) in a 64-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L21B) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Apr-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 04-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine administered to patient). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vial expired on 01-Apr-2022 that was initially stored in the refrigerator on 04-Apr-2022 and then administered on 04-Apr-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine administered to patient) and PRODUCT STORAGE ERROR (The vial expired on 01-Apr-2022 that was initially stored in the refrigerator on 04-Apr-2022 and then administered on 04-Apr-2022) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  The vial was initially stored in the refrigerator on 04-Apr-2022.   The pharmacist reported that vaccine expired in Jun-2022 however the vaccine expired on 01-Apr-2022. The vial had not undergone any temperature excursions. The pharmacist does not have any other information on the patients at that time and would call Moderna when additional information was known. The health care professional further stated to provide missed information and mentioned that 155 patients were vaccinated with expired doses from 02-Apr-2022 to 19-Apr-2022.  No treatment medications were reported.
Pt experienced painful joints about 2 weeks after the immunization.  Was going to several docs and specialists to try to figure out what was wrong.  P reported back the doc said it was reactive arthritis due to the vaccine.
12:00 Client received Pfizer #1 12:01 Client felt tingling in his injection arm 12:02 Client felt lightheaded, black flashes in his vision, and then had full syncope 12:02 Client came to in the chair in observation and felt sweaty but improving. 12:03 Client moved to a cot where he recovered fully over the next 20 minutes.
Patient reports labile INR's ever since vaccine. Previously managed by primary care physician, but now being managed at anticoagulation clinic since 9/2/21 and has referral for hematology.
Son started with fever of 100.2 2 days after shots given. Fever progressed to 103 for the 4th and 5th day after shots given. Fever then lowered to 100.2 for the 6th, 7th & 8th days after shots given. On the 4th day son started with rash on face which progressed to torso then to whole body. Rash faded after 6 days.
5 1/2 x 7 in. erythema with 2"x3" unhal discolored bruise
Bexsero and Menveo administered on same arm; This case was reported by a other health professional via call center representative and described the occurrence of vaccine administered at inappropriate site in a 16-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA660A, expiry date 28th February 2023) for prophylaxis.   Co-suspect products included Men B NVS (Bexsero) (batch number M7455, expiry date 31st December 2022) for prophylaxis and meningococcal B recom vaccine + aloh + omv pre-filled syringe device (Bexsero Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 17th June 2022, the patient received Menveo, Bexsero and Bexsero Pre-Filled Syringe Device. On 17th June 2022, unknown after receiving Menveo, Bexsero and Bexsero Pre-Filled Syringe Device, the patient experienced vaccine administered at inappropriate site. On an unknown date, the outcome of the vaccine administered at inappropriate site was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 17-Jun-2022 Reporter's comments: The healthcare professional reported that Bexsero and Menveo was administered in the same arm to the patient. The consent to follow up was given. The vaccine administration facility was the same as primary reporter. Additional Supportive Information: The patient received Bexsero and Menveo in the same arm, which led to vaccine administered at inappropriate site.